Introduction {#S1}
============

The Adenosine diphosphate-Ribosylation Factor (ARF) family of proteins belongs to the RAS superfamily of small GTPases and comprises around 30 members in mammals ([@B129]). This family includes 6 ARFs (5 in humans since ARF2 is absent), 21 ARLs, 2 Secretion-Associated RAS-related (SARs) and the TRIpartite Motif-containing protein 23 (TRIM23). ARF1-5 regulate vesicle budding at the Golgi apparatus by recruiting coat complexes ([@B81]; [@B65]). ARF6 localizes to the plasma membrane, as well as endosomes and is involved in actin cytoskeleton dynamics and endocytic recycling ([@B25]). The functions of ARL proteins are more heterogeneous and currently unknown for several of them. ARL2 and ARL3 interact with microtubules and function in tubulin assembly and cytokinesis, respectively, while ARL4C and ARL4D are involved in actin remodeling and regulate cell migration ([@B76]; [@B22]). Our laboratory has shown that ARL13B binds actin and regulates cell migration ([@B4]; [@B14]). Interestingly, several ARLs, namely ARL3, ARL6 and ARL13B are associated with the cilium and play different roles in ciliary biology and signaling pathways associated with this organelle ([@B93]). ARL8B is well characterized and has been shown to localize to lysosomes and regulate several aspects of lysosome biology, such as positioning and motility ([@B68]). Finally, SARs play a well-described role in the budding of COPII-coated vesicles from the ER, while TRIM23 was implicated in antiviral defense and adipocyte differentiation ([@B2]; [@B141]; [@B118]).

Like other GTPases, ARF family proteins switch between an active state, in which proteins are GTP-bound and an inactive state, in which proteins are GDP-bound. For this reason, they are referred to as "molecular switches." Nucleotide exchange is catalyzed by GEFs and GTP hydrolysis is promoted by GAPs. When they are active, ARF proteins associate with membranes via lipid modifications, namely myristoylation, palmitoylation or acetylation and bind effectors. These are responsible for the downstream functions of ARF family proteins and are highly diverse. Among the effectors identified are coat complexes and adaptors, cytoskeleton-binding proteins and tethering factors ([@B26]). The functions of ARF and ARL proteins, as well as their GEFs and GAPs are thoroughly reviewed in two excellent recent reviews ([@B93]; [@B129]).

Since ARFs and their regulators play essential functions in cell cycle, cytoskeleton remodeling, cell migration and adhesion, it is not surprising that they can be subverted by cancer cells for proliferation, migration and invasion. Indeed, the expression and/or activity of several ARF family proteins and their GEFs and GAPs has been shown to be modulated in several types of cancer ([Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}). Moreover, the amplification and overexpression of ARF family genes, as well as the overexpression of their GEFs and GAPs, and variance in post-translational modifications are the most commonly detected alterations thought to be implicated in cancer. Here, we review the members of the ARF family and their activity regulators and effectors that have been implicated in cancer, and can either function as oncogenes or tumor suppressors and propose possible therapeutic approaches to target ARF family proteins or their effectors, GEFs and GAPs.

###### 

Expression of ARF family members in human neoplastic tissues and cancer cells.

  **ARF/ARL**   **Expression**   **Cancer type**                                                                               **References**
  ------------- ---------------- --------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------
  ARF1          **↑**            Breast, Colon/Colorectal, Gastric, Liver, Ovarian, Osteosarcoma, Prostate                     [@B106]; [@B91]; [@B66]; [@B131]; [@B121]; [@B23]; [@B43]
  ARF3          **↑**            Breast                                                                                        [@B60]
                **↓**            Gastric                                                                                       [@B18]
  ARF4          **↑**            Breast, Glioma, Lung, Ovarian                                                                 [@B144]; [@B9]; [@B57]; [@B145]
  ARF6          **↑**            Breast, Gastric, Glioma, Liver, Lung, Melanoma, Pancreatic, Prostate, Renal Cell Carcinoma    [@B50]; [@B58]; [@B69]; [@B104]; [@B96]; [@B162]; [@B49]; [@B82]; [@B117]; [@B156]
  ARL2          **↑**            Bladder, Cervical, Liver                                                                      [@B51]; [@B77]; [@B113]
                **↓**            Breast                                                                                        [@B6]
  ARL3          **↓**            Glioma                                                                                        [@B138]
  ARL4C         **↑**            Colon/Colorectal, Gastric, Glioma, Head and Neck, Liver, Lung, Muscle, Renal Cell Carcinoma   [@B39]; [@B45]; [@B40]; [@B59]; [@B19]; [@B47]; [@B63]
                **↓**            Ovarian                                                                                       [@B127]
  ARL4D         **↑**            Glioma                                                                                        [@B21]
  ARL5A         **↑**            Colon/Colorectal                                                                              [@B139]
  ARL6          **↑**            Muscle                                                                                        [@B87]
  ARL11         **↓**            Breast, Leukemia, Lung, Ovarian, Prostate                                                     [@B11]; [@B114]; [@B155]; [@B125]
  ARL13B        **↑**            Breast, Gastric                                                                               [@B124]; [@B13]
  ARL14         **↑**            Bladder                                                                                       [@B136]
  ARFRP1        **↑**            Gastric                                                                                       [@B92]
  TRIM23        **↑**            Gastric                                                                                       [@B153]
  SARI A        **↑**            Liver                                                                                         [@B52]
  SAR1B         **↓**            Colon/Colorectal                                                                              [@B61]

(↑), upregulated; (↓), downregulated.

###### 

Expression of ARF GEFs in human neoplastic tissues and cancer cells.

  **ARF GEF/GAP**   **Expression**   **Cancer type**                                                                                                                               **References**
  ----------------- ---------------- --------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------
  Cytohesin 1       **↑**            Leukemia/Lymphoma                                                                                                                             [@B133]
  Cytohesin 2       **↑**            Colon/Colorectal, Liver                                                                                                                       [@B149]; [@B108]; [@B117]
  Cytohesin 3       **↑**            Liver                                                                                                                                         [@B38]
  BRAG2             **↑**            Breast, Lung, Pancreatic                                                                                                                      [@B53]; [@B97]; [@B94]; [@B104]
  BIG2              **↑**            Pancreatic                                                                                                                                    [@B109]
  EFA6              **↑**            Glioma, Renal Cell Carcinoma                                                                                                                  [@B79]; [@B49]
                    **↓**            Breast, Brain, Ovarian                                                                                                                        [@B115]; [@B132]; [@B159]
  ASAP1             **↑**            Bladder, Breast, Colon/Colorectal, Esophagus, Gastric, Head and Neck, Melanoma, Ovarian, Pacreatic, Prostate, Renal Cell Carcinoma, Thyroid   [@B31]; [@B107]; [@B84]; [@B98]; [@B56]; [@B80]; [@B120]
                    **↓**            Cervical                                                                                                                                      [@B98]
  ASAP3             **↑**            Liver, Lung, Ovarian                                                                                                                          [@B105]; [@B32]; [@B143]
  AGAP1             **↑**            Leukemia/Lymphoma                                                                                                                             [@B48]
  AGAP2             **↑**            Bladder, Breast, Brain, Cervical, Colon/Colorectal, Gastric, Glioma, Head and Neck, Leukemia/Lymphoma, Liver, Lung, Ovarian, Prostate         [@B1]; [@B70]; [@B132]; [@B86]; [@B10]; [@B148]; [@B27]
  GIT1              **↑**            Breast, Cervical, Colon/Colorectal, Head and neck, Liver, Lung, Melanoma, Renal Cell Carcinoma                                                [@B158]; [@B16]; [@B62]; [@B112]; [@B17]; [@B89]
  GIT2              **↓**            Breast                                                                                                                                        [@B126]
  SMAP1             **↓**            Colon/Colorectal                                                                                                                              [@B119]
  ARFGAP3           **↑**            Prostate                                                                                                                                      [@B100]
  ARAP3             **↓**            Gastric                                                                                                                                       [@B151]

(↑), upregulated; (↓), downregulated.

ARF Family Proteins and Their Activity Regulators and Effectors That Can Function as Oncogenes {#S2}
==============================================================================================

Dysregulation of expression and/or activity of ARF family proteins and/or their effectors, GEFs and GAPs has been associated with enhanced cell migration, invasion and proliferation in several types of cancer. In this section, we review the ARF family members, as well as their activity regulators and effectors that have been found overexpressed in cancer and play essential roles in cancer progression ([Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}).

ARF1 {#S2.SS1}
----

ARF1 plays a central role in maintaining the structure and function of the Golgi apparatus and is highly expressed in breast, prostate and ovarian cancers ([@B121]; [@B23]; [@B43]). In the context of cancer, ARF1 has an important function in inter- and intracellular signaling, cell cycle regulation and DNA repair, as well as necrosis and apoptosis ([@B28]; [@B43]). Moreover, ARF1 regulates breast cancer cell adhesion and proliferation, being essential for EGF-mediated phosphorylation of Focal Adhesion Kinase (FAK) and Src ([@B121]). Furthermore, ARF1 sensitizes MDA-MB-231 breast cancer cells to the anti-tumor drugs actinomycin D and vinblastine through ERK and Akt signaling ([@B90]). In prostate cancer, ARF1 promotes tumorigenesis by controlling MAPK activation and cell growth ([@B23]). In myeloma cells, ARF1 expression promotes cell proliferation and inhibits cell adhesion, controlling proliferation- and cell adhesion-mediated drug resistance ([@B150]). Finally, ARF1 is upregulated in ovarian tumors, when compared with adjacent non-cancerous tissues and its overexpression is associated with ovarian cancer cell proliferation and migration through the PhosphoInositide 3-Kinase (PI3K) pathway ([@B43]).

ARF3 {#S2.SS2}
----

Like ARF1, ARF3 is involved in the recruitment of coat complexes to the Golgi apparatus, activation of PhosphoLipase D (PLD) and PI-kinases. Recently, ARF3 expression was positively correlated with breast cancer clinical stages, being upregulated in 92.8% of malignant cases, relative to benign ones ([@B60]). Indeed, ARF3 mRNA and protein expression levels are upregulated in human breast cancer cell lines and tissues ([@B60]). Moreover, ARF3 overexpression promotes breast cancer cell proliferation by regulating the cell-cycle G1/S transition, through inhibition of FOXO1 transcription factor activity ([@B60]). Additionally, *ARF3* was found to be a candidate gene involved in the progression of pregnancy-associated breast cancer, based on integrated analysis of microarray profile datasets ([@B160]).

ARF4 {#S2.SS3}
----

Together with the upregulation of *COPB1* and *USO1*, which encode for the COPI subunit β1 and General vesicular transport factor p115, respectively and regulate ER-Golgi trafficking, ARF4 has been reported to be upregulated in breast cancer patient samples ([@B57]). This establishes a role for *ARF4*, *COPB1*, and *USO1* in the regulation of breast cancer cell growth and invasion through the retrograde transport of proteins from the Golgi to ER via COPI-coated vesicles. ARF4 has also been associated with the regulation of breast cancer cell migration in response to Phorbol-12-Myristate 13-Acetate (PMA) ([@B64]). Finally, ARF4 has been found upregulated in other types of epithelial cancers, such as ovarian cancer ([@B145]) and lung adenocarcinomas ([@B9]). In U373MG human glioblastoma-derived cells, ARF4 has an anti-apoptotic function by reducing the generation of ROS in response to the expression of B-cell lymphoma 2 (Bcl-2)-Associated X protein (Bax) or the synthetic retinoid derivative N-(4-hydroxyphenyl) retinamide ([@B144]).

ARF6 {#S2.SS4}
----

ARF6 is well characterized in the context of cancer and known to regulate cancer cell invasion and metastasis, as well as tumor angiogenesis and growth (reviewed in [@B55]; [@B78]). Clinically, ARF6 expression and activation of its downstream signaling pathways was determined and associated with poor overall survival of breast, lung adenocarcinoma, pancreatic ductal adenocarcinoma and head and neck cancer patients ([@B78]). Also, elevated ARF6 expression has been reported in prostate and non-small cell lung and squamous cell lung cancers ([@B69]; [@B96]). Moreover, a direct correlation between ARF6 protein expression levels and breast cancer cell invasiveness was shown in breast cancer cell lines with different invasive abilities ([@B50]). Furthermore, ARF6 silencing impairs invasion of breast cancer, melanoma and glioma ([@B50]; [@B58]; [@B42]), providing evidence that ARF6 is an important driver of cancer cell invasion and metastasis. In lung adenocarcinoma, the combined expression of ARF6, its GEF BRAG2/GEP100 and EGFR is associated with decreased patient survival ([@B104]). ARF6 is known to recruit actin binding proteins, adhesion molecules and proteases, which are essential for invadopodia formation and ExtraCellular Matrix (ECM) degradation ([@B123]). Indeed, ARF6 activation was shown to promote invadopodia formation through activation of Rho- and Rac1-dependent pathways ([@B99]). ARF6 is also necessary for Human Growth Factor (HGF)-induced tumor angiogenesis and growth ([@B54]). It has also been shown that ARF6 coordinates signaling and function of several oncogenes, like *EGFR*, *ERBB2*, and *CTNNB1*, which encode for EGFR, HER2, and β-catenin, respectively ([@B97]; [@B94]; [@B111]; [@B157]). In agreement, it was recently observed that ARF6 is a downstream target of mutant KRAS and maintains KRAS-induced ERK activation, promoting pancreatic tumorigenesis ([@B82]). Also, ARF6 was linked to liver cancer through the regulation of the endocytic recycling of CD147, a tumor-related adhesive protein that promotes invasion of liver cancer cells ([@B117]). Moreover, the increased expression of ARF6-CD147 signaling components, like Cytohesin 2/ARNO, an ARF6 GEF and Rac1 were associated with poor overall survival of hepatocellular carcinoma patients ([@B117]).

ARF GEFs and GAPs {#S2.SS5}
-----------------

Amplification of ARF GAPs has been associated with several types of cancer. Indeed, AGAP2, which acts on ARF1 and ARF5, promotes cancer cell survival, migration and invasion in gliobastomas ([@B116]). Moreover, ASAP1 expression is correlated with the metastatic potential of melanoma, prostate cancer and colorectal cancer and increased invasiveness of breast cancer and melanoma cells ([@B31]; [@B107]; [@B84]; [@B98]). Cancer cell migration requires coordinated assembly and disassembly of cell-ECM contacts, mediated by FAs. Indeed, several ARF GAPs, namely ASAP1, ASAP2, GIT1 and GIT2 have been found to be localized at FAs ([@B12]). GIT1, which inactivates ARF6 specifically, is highly expressed in several types of cancers, including breast, cervical, colon and liver ([@B158]; [@B16]; [@B62]; [@B112]). Moreover, GIT1 interacts with Paxillin and p21-activated kinase Interacting eXchange factor (PIX) at FAs, regulating cancer cell migration ([@B101]). Furthermore, GIT1 silencing has been shown to inhibit cell migration and invasion in oral squamous cell carcinoma and breast cancer ([@B16]; [@B62]). Although GIT1 is associated with several types of cancer, it is not clear whether ARF6 inactivation by GIT1 is a requirement for cancer progression.

Regarding the ARF GEFs, BRAG2/GEP100 and EFA6, which activate ARF6 specifically, are known to be involved in cancer progression. BRAG2 induces breast cancer cell invasion and metastasis ([@B97]). After BRAG2 binding to phosphorylated EGFR, ARF6 is activated in breast cancer cells, leading to the formation of invadopodia with recruitment of Cortactin, Paxillin and the ARF GAP ASAP1 ([@B107]; [@B97]). In lung adenocarcinoma, the pathway involving EGFR, ARF6 and ASAP1 was reported to be associated with reduced patient survival ([@B104]). In melanoma cells, the stimulation of WNT5A, a member of the Wnt signaling pathway, induces ARF6 activation mediated by BRAG2, which facilitates the release of β-catenin from cadherin and stimulates tumor cell invasion ([@B42]).

Concerning the EFA6 GEFs, they regulate tumor progression either positively or negatively, depending on the cancer types. In glioma and renal carcinoma, EFA6 GEFs are upregulated, controlling cancer cell invasion ([@B79]; [@B49]). The ARF GEFs Cytohesin 1-3 function as regulators of cytoskeleton reorganization and integrin signaling ([@B72]) and target ARF6, among other ARFs. In prostate cancer, inhibiton of Cytohesin 1 by siRNA, reduces the pro-tumorigenic role of Insulin Growth Factor Receptor (IGFR) signaling ([@B142]), suggesting that this ARF GEF could be targeted to impair prostate cancer progression. Additionally, the ectopic expression of the constitutively active form of ARF6 (ARF Q67L) enhances melanoma progression and metastasis *in vivo* ([@B99]).

ARL2 {#S2.SS6}
----

ARL2 was first reported to behave as a tumor suppressor in breast cancer. However, several publications thereafter suggest that this might not be the case for other types of cancers. Indeed, it was shown that BART binds to active ARL2, inhibiting the inactivation of RhoA and thus impairing the invasive potential of pancreatic cancer cells ([@B130]). Other studies evaluated the effect of ARL2-targeting microRNAs (miRs). In particular, miR-214 was found to suppress growth and increased apoptosis in colon cancer ([@B88]). Moreover, miR-214 was studied in the context of cervical cancer, in which its expression is able to suppress proliferation, migration and invasion of cancer cells ([@B113]). Two other miRs were found to be involved in cancer progression. miR-497-5p overexpression leads to a decrease in osteosarcoma cell proliferation and an increase in apoptosis ([@B128]). On the other hand, miR-195, which is regulated by Urothelial Cancer Associated 1 (UCA1) targets ARL2 in bladder cancer ([@B77]). Studies performed in mice showed that bladder tumor size is reduced upon UCA1 downregulation and the expression of miR-195 is increased, resulting in ARL2 downregulation. The authors concluded that the effects in bladder cancer cells mediated by UCA1/miR-195/ARL2 are a consequence of mitochondrial metabolism modulation, which regulates cancer cell survival ([@B77]). Finally, *ARL2* was found to be overexpressed in human hepatocellular carcinoma samples by gene expression analysis ([@B51]).

ARL4 {#S2.SS7}
----

*ARL4C* was initially found to be upregulated at the mRNA level in both colorectal and lung cancers ([@B39]). Moreover, the same authors found that ARL4C silencing leads to a decrease in cell migration and invasion *in vitro*, and proliferation both *in vitro* and *in vivo*, dependently on aberrant Wnt/β-catenin and EGF/RAS signaling. ARL4C was also found to be overexpressed in leiomyosarcoma type II ([@B45]). Furthermore, analysis of ARL4C expression in colorectal cancer samples revealed that this ARL is more expressed in tumor samples, comparing with adjacent normal tissue ([@B20]). The prognostic value of ARL4C in colorectal cancer was also evaluated and the same authors concluded that patients with higher expression of ARL4C have lower survival on average ([@B20]). In the case of lung and tongue squamous cell carcinoma, it was found that ARL4C promotes proliferation and migration of cells from these types of cancers ([@B40]). Interestingly, ARL4C overexpression in lung tumors was shown to be due to hypomethylation of *ARL4C* in the 3′-UTR through Ten-Eleven Translocation methylcytosine dioxygenases (TETs) ([@B40]). Recently, several groups investigated the role of ARL4C in different types of cancer. *ARL4C* was identified as a peritoneal dissemination-associated gene and found to be highly expressed in gastric cancer cells ([@B59]). Indeed, ARL4C silencing impairs migration and invasion of gastric cancer cells *in vitro* ([@B59]). Moreover, the reduced expression of ARL4C leads to a decrease of the epithelial-mesenchymal transition (EMT) marker SLUG, as well as a reduction in lamellipodia and filopodia formation in gastric cancer cells ([@B59]). ARL4C expression was also found to be increased in primary and metastatic hepatocellular carcinoma. Additionally, the decrease in ARL4C expression leads to the impairment of cancer cell proliferation and migration *in vitro* and *in vivo*, as well as a reduction in expression of PI3K Catalytic subunit Delta (*PI3KCD*) mRNA and activity of Akt ([@B47]). This suggests that the molecular mechanisms involved in the role of ARL4C in hepatocellular carcinoma are different from those in lung and colorectal cancers. Furthermore, upregulation of ARL4C was associated with a poor prognosis in endometriosis-associated ovarian cancer, Phosphatase and TENsin homolog deleted on chromosome 10 (PTEN)-deficient glioblastomas and renal cell carcinomas ([@B134]; [@B19]; [@B63]). Another ARL4 isoform, ARL4D was first identified as a glioma-associated antigen ([@B103]). Later, a study revealed that ARL4D expression in gliomas is dependent on the loss of PTEN tumor suppressor and consequent activation of the Akt/mammalian Target of Rapamycin (mTOR) pathway ([@B21]).

ARL5, ARL6, ARL8, ARL14, and ARFRP1 {#S2.SS8}
-----------------------------------

ARL5A was found to be highly expressed in colorectal cancer and a target of miR-202-3P ([@B139]). Furthermore, the same study demonstrated that the downregulation of ARL5A and miR-202-3P expression leads to a similar reduction in colorectal cancer cell proliferation ([@B139]).

In rhabdomyosarcoma, ARL6 was demonstrated to be upregulated in cilia-dependent cancer cells and its silencing decreases cell proliferation ([@B87]). Additionally, ARL6 downregulation leads to an increase in apoptosis of rhabdomyosarcoma cancer cells due to defects in ciliogenesis and a reduction of Hedgehog (Hh) signaling ([@B87]).

In the case of ARL8, depletion of ARL8B leads to a reduction in invasion and protease secretion by prostate cancer cells ([@B30]). Moreover, ARL8B silencing prevents the growth of prostate tumors in mice ([@B30]). Furthermore, the same study revealed that the role of ARL8B in cancer progression is dependent on its function in regulation of lysosomal motility and fusion.

A recent study reported that *ARL14* silencing in lung cancer cells blocks ERK1/2 and p28 signaling and upregulates the cell death inducing DFFA-like effector C (CIDEC), leading to cell cycle arrest ([@B44]). Also, hypermethylation of *ARL14* was found to be correlated with a poor prognosis of bladder cancer patients ([@B136]).

Finally, in the case of ARFRP1, it was found upregulated in gastric cancer ([@B92]).

ARL13B {#S2.SS9}
------

The role of ARL13B in medulloblastoma and gastric cancer progression, dependent on cilia and Hh signaling was described recently ([@B5]; [@B124]). Shao and co-authors showed that ARL13B promotes proliferation, migration and invasion of gastric cancer cells both *in vitro* and *in vivo*, through activation of Smoothened (Smo) and consequent activation of Hh signaling ([@B124]). In medulloblastoma, ARL13B depletion was reported to lead to a decrease in cilia-dependent oncogenic Hh signaling ([@B5]). Recently, our group found evidence that ARL13B plays a role in breast tumorigenesis and cancer progression, likely independently of cilia. Indeed, depletion of ARL13B in breast cancer cells leads to a reduction in cell migration and invasion *in vitro* and impaired tumor progression *in vivo* ([@B13]). Moreover, our results revealed a new mechanism to explain the role of ARL13B in tumor progression, through the modulation of cell-ECM adhesion and integrin-mediated signaling.

Non-Muscle myosin heavy chain II A (NMIIA) was identified by us as an effector of ARL13B, since it binds to the active form of this protein ([@B14]). In the same study, we found that NMIIA mediates ARL13B binding to actin and that both proteins are required for the formation of circular dorsal ruffles (CDRs), which are actin-rich structures required for cell migration ([@B14]). Our group also found that GTP-bound ARL13B interacts with NMIIA in breast cancer cells ([@B13]). Other studies reported the role of NMIIA in different types of cancers and indicate that *NMIIA* can function as a tumor suppressor or oncogene. For example, NMIIA was found to be overexpressed in gastric cancer ([@B85]) and promote tumor progression in different types of cancers ([@B24]; [@B67]; [@B83]; [@B154]). On the other hand, *NMIIA* was described as a potential tumor suppressor gene in squamous cell carcinomas, since the downregulation of NMIIA associates with poor survival, increased cancer cell invasion and decreased p53 stabilization, *in vitro* and *in vivo* ([@B122]). These studies are described in greater detail in two recent reviews ([@B110]; [@B137]). Other evidence suggests that NMIIA expression is increased in colorectal cancer and that NMIIA enhances tumor aggressiveness through activation of mitogen-activated protein kinase (MAPK) Akt signaling, which promotes EMT ([@B135]). NMIIA was also found to be a promoter of EMT in pancreatic cancer ([@B164]). Moreover, in the same study it was observed that NMIIA downregulation results in decreased invasion and metastasis formation through the suppression of canonical Wnt/β-catenin signaling ([@B164]).

TRIM23 and SAR1 {#S2.SS10}
---------------

In hepatocellular carcinomas, miR-194, which targets TRIM23 was found to be downregulated. Moreover, overexpression of miR-194 decreases cell migration, invasion and metastasis of hepatocellular carcinoma cells, through inhibition of Nuclear Factor (NF)-κb activity ([@B3]). Furthermore, TRIM23 was found to be overexpressed in gastric cancer, both in cell lines and tissues ([@B153]).

In the case of SAR1, it was found to be overexpressed in liver cancer ([@B52]). More recently, SAR1b was identified as a promoter of drug resistance, namely mTOR Complex (mTORC) inhibitors, in liver tumor initiating stem cells and hepatocellular carcinoma cells ([@B146]).

Arf Family Proteins and Their Activity Regulators and Effectors That Can Function as Tumor Suppressor Genes {#S3}
===========================================================================================================

In some cases, the expression of membrane traffic regulators, namely ARF family proteins or their effectors, GEFs or GAPs is found downregulated in tumor cells ([Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}).

ARF3 {#S3.SS1}
----

Besides its behavior as an oncogene in breast cancer, ARF3 has been found downregulated in gastric cancer ([@B18]). In fact, ARF3 expression is significantly decreased in gastric cancer stages I-III, when compared with paired normal gastric mucosa tissues, indicating that this protein could be a marker for gastric cancers without metastasis. The clinical significance of these results remains to be elucidated.

ARF GEFs and GAPs {#S3.SS2}
-----------------

SMAP1 or ARFGAP1 is a member of the ARF GAP family that is involved in clathrin-dependent endocytosis of the Transferrin receptor and E-cadherin ([@B74]; [@B71]). In colorectal cancers with microsatellite instability, short deletions or insertions frequently occur in *SMAP1*, generating a premature termination codon. This results in reduced or abolished SMAP1 protein levels in colorectal tumors ([@B73]).

Unlike other phosphotyrosine proteins that are usually overexpressed or hyperphosphorylated in gastric tumor cells, the ARF GAP ARAP3 is downregulated in gastric cancer tissues ([@B151]). Furthermore, GIT2 stabilizes FAs by reducing Rac1 activity in the breast cancer cell line MDA-MB-231 ([@B37]). Also, in a gene expression profile analysis of breast cancer patient samples, GIT2 was found downregulated in a group of lymph node-positive breast cancer patients ([@B126]).

Finally, EFA6 GEFs are downregulated in breast, brain and ovarian cancers ([@B115]; [@B132]; [@B159]).

ARL2 {#S3.SS3}
----

ARL2 has been shown to directly influence α/β-tubulin polymerization in the breast cancer cell line MCF-7 ([@B7]). Moreover, MCF-7 cells expressing higher levels of ARL2 are more sensitive to cytotoxic agents, while cells with reduced expression of ARL2 show enhanced resistance to the same agents ([@B8]). This resistance is mediated by Protein Phosphatase 2A (PP2A), whose activity is regulated by ARL2. When ARL2 is decreased, impaired dephosphorylation of p53 by PP2A occurs, leading to an increase of phosphorylated p53, which alters PP2A localization and causes a chemo-resistant phenotype ([@B8]). Moreover, *in vitro* assays using breast cancer cells depleted for ARL2 show less contact inhibition, an enhanced clonogenic potential and increased proliferation than control cells ([@B6]). Furthermore, using orthotopic mouse models, depletion of ARL2 was shown to impair cancer progression ([@B6]). Additionally, ARL2 downregulation was recently correlated with more aggressive cases of glioma and a lower survival of the patients ([@B140]). Finally, ARL2 overexpression inhibits proliferation, as well as migration and tumorigenicity of glioma cells, through regulation of the receptor tyrosine kinase AXL, a known regulator of glioma tumorigenesis ([@B140]).

ARL3, ARL4, and SAR1 {#S3.SS4}
--------------------

*ARL3* mRNA and protein expression were shown to be downregulated in gliomas ([@B138]). Furthermore, an extensive bioinformatics analysis suggested that ARL3 plays a role in angiogenesis and immune cell infiltration in the tumor microenvironment ([@B138]).

ARL4C was associated with reduced metastatic potential of ovarian cancer cells, in which it inhibits cell motility but not cell proliferation ([@B127]). Furthermore, *ARL4C* mRNA expression is lower in ovarian cancer samples of patients with a poor treatment response, while patients with higher ARL4C expression show increased overall survival ([@B127]).

Finally, SAR1B was identified as a potential metastatic suppressor in colorectal cancer, through a targeted proteomic approach ([@B61]). Also, migration and invasion assays showed that SAR1B silencing leads to an increase in colorectal cancer cell motility and invasive capacity ([@B61]).

ARL11 {#S3.SS5}
-----

*ARL11*, also known as ADP Ribosylation factor-Like Tumor Suppressor gene 1 (*ARLTS1*) was described as a potential low-penetrance tumor suppressor gene in different types of cancers, such as breast cancer, melanoma and chronic lymphocytic leukemia ([@B11]). Different variants of *ARLTS1* have been associated with familial and sporadic cancers, where the mutations Trp149Stop and Cys148Arg are the most studied ([@B155]). The nonsense mutation Trp149Stop leads to the production of a truncated protein unable to bind GTP, which results in decreased apoptotic potential of the cell ([@B114]). Both variants were found to be associated with predisposition to familial breast cancer and, more recently to familial hematological malignancies ([@B11]; [@B35]; [@B46]). Additionally, the Cys148Arg variant was associated with melanoma and both familial and sporadic colorectal cancers ([@B34], [@B36]; [@B15]). Furthermore, *ARLTS1* expression was found to be decreased in different types of tumors, including ovarian, lung and prostate cancer, as well as chronic lymphocytic leukemia ([@B155]; [@B125]). More recently, a study in ovarian cancer suggested that ARLST1 increases tumor cell sensitivity to chemotherapeutic agents by regulating apoptosis ([@B152]).

Therapeutic Strategies {#S4}
======================

As can be concluded from [Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}, several ARFs and ARF GEFs and GAPs are overexpressed in different types of cancers. Therefore, therapeutic strategies aiming to inhibit the expression of these proteins can be proposed. Other approaches like the use of small GTPase inhibitors that impair GTP binding or the binding to membranes, the blockade of GEF activity or ARF-GEF interaction, should also be considered. Furthermore, the stimulation of GAP activity/expression and the inhibition of the interaction with downstream effectors or the function/expression of these effectors can also be envisaged ([Figure 1](#F1){ref-type="fig"}). For instance, the inhibitor LM11 can abolish specifically ARF1 activation through the blockade of the binding of the ARF GEF Cytohesin 2/ARNO ([@B33]; [@B147]). Indeed, it has been shown that the aggressiveness of breast tumors that overexpress ARF1 is reduced after treatment with this inhibitor through the decrease in cell invasion and proliferation and increased apoptosis ([@B121]; [@B147]). Also, the small inhibitor EXO2 reduces ARF1 activation and effectively impairs the proliferation of prostate cancer cells by blocking ERK1/2 activation ([@B75]). Moreover, EXO2 inhibits invasion of prostate cancer cells and induces their apoptosis. Furthermore, the same study shows that the simultaneous blockade of ARF1 and RAS activation in prostate cancer is a potential targeted strategy to prevent the development of this type of tumor ([@B75]).

![Putative therapeutic strategies to target ARF proteins, GEFs, GAPs and effectors. **(A)** In the case of ARF family members that can act as oncogenes, their expression or activity could be downregulated (1); GEF activity or expression downregulated (2); ARF-GEF binding blocked or nucleotide binding blocked (3); active ARF binding to membranes (4) or effectors blocked (5); effector function impaired (6); GAP expression or activity upregulated (7). **(B)** Regarding ARF proteins that can act as tumor suppressors, their expression or activity could be upregulated (1); GEF activity or expression upregulated (2); GAP activity or expression downregulated (3).](fcell-08-00217-g001){#F1}

Since some ARF proteins like ARF6 and ARF1, are ubiquitously expressed and perform essential functions in all cell types ([@B28]), targeting the proteins themselves could have dramatic and unwanted consequences. In alternative, targeting their regulators, such as ARF GEFs or GAPs, might represent a viable strategy for the development of specific anti-cancer therapies. Regarding the targeting of ARF GEFs, it has been shown that SecinH3, an ARF GEF inhibitor that impairs both ARF1 and ARF6-dependent signaling, is effective in decreasing the growth of breast cancer xenografts and reducing lung metastasis ([@B163]), while suppressing angiogenesis of melanoma and lung carcinoma tumors ([@B42]; [@B54]). Thus, inhibitors of the ARF6-dependent signaling pathway could be useful to control specifically tumor invasion and angiogenesis.

It has been observed that several ARF GAPs are overexpressed in cancer ([Table 2](#T2){ref-type="table"}), even though overexpression of ARF GAPs does not imply increased GAP activity. For instance, AGAP2 expression in chronic myeloid leukemia cells and prostate cancer is regulated by Specific Protein 1 (SP1) and ATRA ([@B27]). Additionally, the authors observed that the treatment of cells of these types of cancer with the polyphenol curcumin, leads to a decrease in ATRA-mediated AGAP2 expression ([@B27]; [@B41]). This data illustrates the relevance of regulating ARF GAP expression levels in cancer. On the other hand, it was observed that QS11, the only inhibitor of ARF GAPs known, binds to ARF GAP1 and inhibits the activity of this GAP on ARF1 and ARF6 ([@B161]; [@B165]). Interestingly, it was observed that QS11 blocks migration of metastatic breast cancer cells, *in vitro* ([@B161]). Thus, inhibitors of ARF GAP activity could also be effective in controlling cancer cell migration and invasion.

Inhibition of the expression or function of downstream effectors of ARF family proteins is also a plausible strategy to impair the oncogenic potential of ARFs and ARLs. An interesting candidate is NMII. Indeed, several types of cancer exhibit differential expression and/or activation of NMII isoforms, leading to alterations in cell migration and invasion that are involved in tumorigenesis ([@B102]). Moreover, we found that NMIIA is an effector of ARL13B ([@B14], [@B13]). Furthermore, blebbistatin inhibits the ATPase activity of NMIIA and has been found to block invasiveness of both breast cancer cells ([@B24]) and pancreatic adenocarcinoma cells ([@B29]), and is phototoxic in human cancer cells under exposure to blue light ([@B95]).

Conclusion and Perspectives {#S5}
===========================

Members of the RAS superfamily of small GTPases are master regulators of all the steps involved in membrane traffic. Thus, it is not surprising that many of them are hijacked by cancer cells to enhance their capacity to form a tumor and spread to other organs. In particular, ARF family proteins, their GEFs, GAPs and effectors are often upregulated in expression and/or activity in several types of cancer. Moreover, upregulated expression/activity can be linked to enhanced cancer progression and aggressiveness. Therefore, these proteins are good candidates to serve as therapeutic targets and, indeed several strategies have already been proposed and tested. These include the targeting of ARF proteins themselves or their GEFs, GAPs or effectors. While our knowledge of the GEFs, GAPs and effectors of ARFs is fairly complete, much less is known about the functions and identity of GEFs, GAPs and effectors of ARL subfamily members. Hence, the knowledge about these molecular players should be developed in order to find new therapeutic strategies for cancer types where ARLs or their regulators/effectors are subverted. Since most ARF family proteins are ubiquitous and required for essential cellular functions, the targeting of specific effectors and GEFs/GAPs could ensure tissue/function specificity. Nevertheless, specificity could also be achieved through targeted delivery of vectors/drugs.

In conclusion, the study of the mechanisms subverted by cancer cells involving ARF family proteins and their regulators of activity and effectors can shed light on the functions of these proteins and simultaneously provide clues about new therapeutic targets and strategies, which continue to be a pressing need in the cancer field.
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4-HPR

:   N-(4-hydroxyphenil retinamide)

Akt

:   Protein kinase B

ARF

:   ADP-Ribosylation Factor

ARL

:   ARF-Like

ARLTS1

:   ADP-Ribosylation factor-Like Tumor Suppressor gene 1

ATRA

:   All-*Trans* Retinoic Acid

BART

:   Binder of ARL Two

Bax

:   B-cell lymphoma 2-Associated X protein

CDR

:   Circular Dorsal Ruffle

CIDEC

:   Cell Death Inducing DFFA-like Effector C

ECM

:   ExtraCellular Matrix

EGF

:   Epidermal Growth Factor

EGFR

:   Epidermal Growth Factor Receptor

EMT

:   Epithelial-Mesenchymal Transition

ER

:   Endoplasmic Reticulum

ERK

:   Extracellular signal-Regulated Kinase

FA

:   Focal Adhesion

FAK

:   Focal Adhesion Kinase

FOXO1

:   Forkhead bOX O1

GAP

:   GTPase-Activating Protein

GDP

:   Guanosine DiPhosphate

GEF

:   Guanine nucleotide Exchange Factor

GTP

:   Guanosine TriPhosphate

HER2

:   Human Epidermal growth factor Receptor 2

HGF

:   Human Growth Factor

Hh

:   Hedgehog

IGFR

:   Insulin Growth Factor Receptor

MAPK

:   Mitogen-Activated Protein Kinase

miRs

:   microRNAs

mTOR

:   mammalian Target of Rapamycin

mTORC

:   mammalian Target of Rapamycin Complex

NF

:   Nuclear Factor

NMIIA

:   Non-Muscle Myosin heavy chain II A

PAK

:   p21-Activated Kinase

PI

:   PhosphoInositide

PI3K

:   PhosphoInositide 3-Kinase

PI3KCD

:   PhosphoInositide 3-Kinase Catalytic subunit Delta

PIX

:   PAK- Interacting eXchange factor

PLD

:   PhosphoLipase D

PMA

:   Phorbol-12-Myristate 13-Acetate

PP2A

:   Protein Phosphatase 2A

PTEN

:   Phosphatase and TENsin homolog deleted on chromosome 10

Rho

:   RAS homolog gene family member

Rac

:   RAS-related C3 botulinum toxin substrate

ROS

:   Reactive Oxygen Species

SAR

:   Secretion-Associated RAS-related

Smo

:   Smoothened

SP1

:   Specificity Protein 1

Src

:   Rous Sarcoma oncogene cellular homolog

TET

:   Ten-Eleven Translocation methylcytosine dioxygenase

TRIM23

:   TRIpartite Motif-containing protein 23

UCA1

:   Urothelial Cancer Associated 1.
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